IPO Alert: Tarsons Products files IPO papers to raise funds

The Indian healthcare market witnessed a growth of 9.1% in 2020 to reach $198 billion. It is expected to register a growth of around 23% through 2025 and reach $557 billion. On the other hand, medicine spending in India is projected to grow 9-12% over the next five years, giving the country a place among the top 10 countries in terms of medical spending.

Tarsons Products Ltd recently filed a draft paper with the Securities Exchange Board of India to raise funds via an initial public offering, which consists of a fresh issue of shares worth ₹1.5 billion and an offer for sale of up to 13.20 million shares by existing shareholders and promoters.

The company will utilize ₹750 million from the net proceeds for repaying debt and ₹54 million to fund capital expenditure for its new manufacturing facility at Panchla, West Bengal. The remainder of the proceeds will be used for general corporate purposes.

Company Profile

Tarsons Products is an Indian life sciences company engaged in the design, development, manufacturing, and marketing of consumables, reusables, and other benchtop equipment used in laboratories across research organizations, academic institutes, pharmaceutical companies, contract research organizations, diagnostic companies, and hospitals.

The Kolkata, West Bengal-based company has a diversified product portfolio with over 1,700 SKUs (stock-keeping units) across 300 products. It supplies products to over 40 countries through a network of 141 distributors, comprising over 45 authorized distributors and partners.

Key Figures

For FY21, the company reported a total income of ₹2.34 billion, compared to ₹1.80 billion a year ago. Net profit for the period stood at ₹689 million against ₹405 million last year.

Considering the ongoing campaign for environmental protection, one of the main risks facing Tarsons would be potential regulatory actions against the use of plastic. The government has started several campaigns to reduce and eventually ban certain plastic products because it takes a long time for them to biodegrade.

As of now, there are no direct decisions taken by the government on the plastic ban, but if regulations on the production and use of plastic products are made stringent it could have an adverse effect on the company’s business.